Am J Transplant, Volume 18, Suppl 3 Archives - Page 136 of 211 - ATC Abstracts

2018 American Transplant Congress
Heart and Lung Transplantation Outcomes in HIV-Positive Recipients
C. Koval,¹ M. Malinis,² N. Mueller,³ J. Krisl,⁴ M. Hannan,⁵ P. Grossi,⁶ S. Huprikar.⁷
¹Infectious Diseases, Cleveland Clinic, Cleveland, OH; ²Infectious Diseases, Yale University, New Haven, CT; ³Infectious Diseases, University Hospital Zurich, Zurich, Switzerland; ⁴Pharmacy, Houston Methodist Hospital, Houston, TX; ⁵Infectious Diseases, Mater Hospital, Dublin, Ireland; ⁶Infectious Diseases, University Insubria, Varese, Italy; ⁷Infectious Diseases, Mount Sinai Hospital, New York, NY.
Purpose: Data for HIV+ patients receiving heart (HT) or lung transplantation (LT) are limited but appear to demonstrate acceptable outcomes. We aimed to add to…
2018 American Transplant Congress
Medication Reconciliation in Abdominal Transplantation
S. Todd,¹ J. Perryman,² R. Subramanian,² A. Patel,² M. Hawthorne,² R. Buenvenida,² K. Lee,² W. Allison,² D. Lo,² P. Reshamwala.²
¹Department of Pharmacy, Emory University Hospital, Atlanta, GA; ²Emory Transplant Center, Emory University Hospital, Atlanta, GA.
Medication adherence post transplantation is vital. Upon discharge, abdominal transplant patients receive a medication list from the electronic medical record (EMR) and obtain a medication…
2018 American Transplant Congress
Interim Results of the kSORT in the SAILOR Randomized Multicenter Trial
P. Lindner,¹ A. Shroeder,² J. Ekberg,¹ S. Hsieh,² P. Towfighi,² I. Damm,² T. Sigdel,² M. Sarwal.²
¹Sahlgrenska University Hospital, Göteborg, Sweden; ²UCSF, San Francisco.
Background: In a randomized multicenter trial of 222 renal tx recipients treated with steroid minimization and a tacrolimus, MMF based regimen, a novel gene expression…
2018 American Transplant Congress
Evaluation of FlowDSA Crossmatch for Detection of Donor-Specific HLA Antibodies
J. Lee, J. Ryu, A. Choi, E-.J. Oh.
Laboratory Medicine, Seoul St. Mary's Hospital, the Catholic University of Korea, Seoul, Republic of Korea.
Background: Donor-specific HLA antibodies (DSA) are detected by different crossmatch techniques. Flow cytometric crossmatching (FCXM) is sensitive method, but it is subject to false (+)…
2018 American Transplant Congress
Assessment of Immune Cell Profiles in HLA-Sensitized (HS) & Non-HS Patients (Pts) with End Stage Renal Disease (ESRD)
S. Ge,¹ M. Chu,¹ E. Ortiz,¹ A. Vo,² D. Lovato,¹ S. Jordan,² M. Toyoda.¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Background: Chronic inflammation is often seen in pts w/ ESRD. HLA-sensitization may create or be driven by the cytokines responsible for chronic inflammation. Here we…
2018 American Transplant Congress
Sensing T Cell Killing Activity with Granzyme B Activity Probes
Q. Mac,¹ D. Mathews,² J. Kahla,¹ C. Stoffers,¹ O. Delmas,¹ B. Holt,¹ A. Adams,² G. Kwong.¹
¹Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA; ²Department of Surgery, Emory University School of Medicine, Atlanta, GA.
Purpose: We developed activity-based probes that sense Granzyme B (GzmB) activity during alloreactive T cell killing of donor cellsMethods: FITC-labelled GzmB substrate (IEFDSG) was synthesized…
2018 American Transplant Congress
Rictor mTORC2 Signaling Protects Ischemic Liver Injury by Targeting Both Liver Parenchymal and Non-Parenchymal Cells
H. Zhou,¹ Z. Rao,¹ R. Liu,¹ S. Zhou,¹ J. Rao,¹ J. Gu,¹ H. Lu,¹ Y. Xia,¹ X. Wang,¹ Y. Zhai,² L. Lu.¹
¹First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ²David Geffen School of Medicine at University of California-Los Angeles, Los Angeles.
Background and Aims:Mammalian target of rapamycin (mTOR) signaling controls many essential cellular functions. However, the role and its underlying mechanism of Rictor/mTOR complex 2 (mTORC2)…
2018 American Transplant Congress
Ischemic Preconditioning Ameliorates Renal Ischemia-Reperfusion Injury in Mice via Heme Oxygenase-1-Mediated Autophagy
J. Hwang,² H. Choi,¹ M. Kim,² K. Jun,² K. Kown,² S. Park,² J. Kim,² I. Moon.²
¹Clinical Research, Daejeon St. Mary's Hospital, Daejeon, Korea; ²Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Recent data from animal experiments and clinical trials indicate that ischemic preconditioning (IPC) confers protection from renal ischemia-reperfusion (I/R) injury. Nevertheless, the underlying mechanisms for…
2018 American Transplant Congress
Protocolar Biopsies in Patients with Subclinical De Novo DSA in Kidney Transplantation
D. Bertrand,¹ M. Jaureguy,² C. Garrouste,³ J. Sayegh,⁴ N. Bouvier,⁵ S. Caillard,⁶ L. Lanfranco,⁷ A. Galinier,⁸ A. François,⁹ F. Hau,¹⁰ I. Etienne,¹ P. Gatault.¹¹
¹Nephrology Kidney Transplantation Dialysis, CHU Rouen, Rouen, France; ²Nephrology Kidney Transplantation, CHU Amiens, Amiens, France; ³Nephrology Kidney Transplantation, CHU Clermont Ferrand, Clermont Ferrand, France; ⁴Nephrology Kidney Transplantation, CHU Angers, Angers, France; ⁵Nephrology Kidney Transplantation, CHU Caen, Caen, France; ⁶Nephrology Kidney Transplantation, CHU Strasbourg, Strasbourg, France; ⁷Nephrology Kidney Transplantation, CHU Brest, Brest, France; ⁸Nephrology Kidney Transplantation, CHU Poitiers, Poitiers, France; ⁹Pathology, CHU Rouen, Rouen, France; ¹⁰EFS Normandie, EFS Normandie, Rouen, France; ¹¹Nephrology Kidney Transplantation, CHU Tours, Tours, France.
De novo donor-specific antibody (DSA) is associated with antibody-mediated rejection (ABMR) and allograft loss. The aim of our study was to examine the histology associated…
2018 American Transplant Congress
Subclass Distribution of DSA Analyzed by Mass Spectrometry Predicts the Risk of Humoral Rejection
V. Pernin,^1,2 N. Bec,³ C. Larroque,³ C. Duperray,² G. Mourad,¹ M. Lequintrec.^1,2
¹Department of Nephrology, Dialysis and Kidney Transplantation, CHU Lapeyronie, Montpellier, France; ²INSERM U1183 Institute for Regenerative Medicine & Biotherapy (IRMB), Montpellier, France; ³Institut de Recherche en Cancérologie de Montpellier (IRCM)- CRLC Val d'Aurelle - Paul Lamarque - INSERM U896, Montpellier, France.
Background :DSA occurrence after kidney transplant is a main risk factor for humoral rejection and graft loss, however graft outcomes after DSA detection is very…